BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is a serious clinical complication that may compromise liver function because of extensive hepatocyte loss. Therefore, the development of novel and effective therapies for hepatic I/R is critical for the improvement of patient outcome. It has been previously shown that administration of milk fat globule-EGF factor VIII (MFG-E8), a membrane-associated secretory glycoprotein, exerts significant beneficial effects under acute inflammatory conditions through multiple physiological processes associated with tissue remodeling. METHODS: To determine whether administration of recombinant human (rh) MFG-E8 attenuates liver injury in an animal model of hepatic I/R, male adult rats were subjected to 70% hepatic ischemia for 90 min, followed by reperfusion. At the beginning of reperfusion, rats were treated intravenously with normal saline (vehicle) or rhMFG-E8 (160 μg/kg) over a period of 30 min. MFG-E8 levels and various measurements were assessed 4 h after reperfusion. In addition, survival study was conducted in MFG-E8(-/-) and rhMFG-E8-treated wild-type (WT) mice using a total hepatic ischemia model. RESULTS: Liver and plasma MFG-E8 protein levels were significantly decreased after hepatic I/R. Administration of rhMFG-E8 significantly improved liver injury, suppressed apoptosis, attenuated inflammation and oxidative stress, and downregulated NF-κB pathway. We also noticed that rhMFG-E8 treatment restored the downregulated PPAR-γ expression after hepatic I/R. MFG-E8(-/-) mice showed deterioration on survival and, in contrast, rhMFG-E8-treated WT mice showed a significant improvement of survival compared with vehicle-treated WT mice. CONCLUSIONS: MFG-E8-mediated multiple physiological events may represent an effective therapeutic option in tissue injury following an episode of hepatic I/R.
BACKGROUND:Hepatic ischemia-reperfusion (I/R) injury is a serious clinical complication that may compromise liver function because of extensive hepatocyte loss. Therefore, the development of novel and effective therapies for hepatic I/R is critical for the improvement of patient outcome. It has been previously shown that administration of milk fat globule-EGF factor VIII (MFG-E8), a membrane-associated secretory glycoprotein, exerts significant beneficial effects under acute inflammatory conditions through multiple physiological processes associated with tissue remodeling. METHODS: To determine whether administration of recombinant human (rh) MFG-E8 attenuates liver injury in an animal model of hepatic I/R, male adult rats were subjected to 70% hepatic ischemia for 90 min, followed by reperfusion. At the beginning of reperfusion, rats were treated intravenously with normal saline (vehicle) or rhMFG-E8 (160 μg/kg) over a period of 30 min. MFG-E8 levels and various measurements were assessed 4 h after reperfusion. In addition, survival study was conducted in MFG-E8(-/-) and rhMFG-E8-treated wild-type (WT) mice using a total hepatic ischemia model. RESULTS: Liver and plasma MFG-E8 protein levels were significantly decreased after hepatic I/R. Administration of rhMFG-E8 significantly improved liver injury, suppressed apoptosis, attenuated inflammation and oxidative stress, and downregulated NF-κB pathway. We also noticed that rhMFG-E8 treatment restored the downregulated PPAR-γ expression after hepatic I/R. MFG-E8(-/-) mice showed deterioration on survival and, in contrast, rhMFG-E8-treated WT mice showed a significant improvement of survival compared with vehicle-treated WT mice. CONCLUSIONS:MFG-E8-mediated multiple physiological events may represent an effective therapeutic option in tissue injury following an episode of hepatic I/R.
Authors: Kavin G Shah; Rongqian Wu; Asha Jacob; Ernesto P Molmenti; Jeffrey Nicastro; Gene F Coppa; Ping Wang Journal: Intensive Care Med Date: 2011-09-23 Impact factor: 17.440
Authors: Basilia Zingarelli; Maeve Sheehan; Paul W Hake; Michael O'Connor; Alvin Denenberg; James A Cook Journal: J Immunol Date: 2003-12-15 Impact factor: 5.422
Authors: Juan L Contreras; Mario Vilatoba; Christopher Eckstein; Guadalupe Bilbao; J Anthony Thompson; Devin E Eckhoff Journal: Surgery Date: 2004-08 Impact factor: 3.982
Authors: C Théry; A Regnault; J Garin; J Wolfers; L Zitvogel; P Ricciardi-Castagnoli; G Raposo; S Amigorena Journal: J Cell Biol Date: 1999-11-01 Impact factor: 10.539
Authors: Laura W Hansen; Weng Lang Yang; Alexandra C Bolognese; Asha Jacob; Tracy Chen; Jose M Prince; Jeffrey M Nicastro; Gene F Coppa; Ping Wang Journal: Surgery Date: 2017-03-23 Impact factor: 3.982
Authors: Elise Albus; Kathrin Sinningen; Maria Winzer; Sylvia Thiele; Ulrike Baschant; Anke Hannemann; Julia Fantana; Anne-Kathrin Tausche; Henri Wallaschofski; Matthias Nauck; Henry Völzke; Sylvia Grossklaus; Triantafyllos Chavakis; Mark C Udey; Lorenz C Hofbauer; Martina Rauner Journal: J Bone Miner Res Date: 2015-11-09 Impact factor: 6.741
Authors: Adam Khader; Weng-Lang Yang; Andrew Godwin; Jose M Prince; Jeffrey M Nicastro; Gene F Coppa; Ping Wang Journal: Crit Care Med Date: 2016-08 Impact factor: 7.598